The present study provides a better understanding of the H+‐dependent sugar cotransporter in TP53 mutant PDA progression and SLC45A4 may be a potential target with respect to developing therapeutic strategies. This evidence concerns the gene SLC45A4 and Patent ductus arteriosus.